文献速递前列腺癌

老年转移性激素敏感性前列腺癌患者接受多西他赛治疗的结局

Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer.
PubMed 文献 · Prostate Cancer Prostatic Dis · 2021-05-18

该研究为CHAARTED试验的事后分析,比较≥70岁与<70岁转移性激素敏感性前列腺癌(mHSPC)患者接受多西他赛+ADT的疗效与安全性。结果显示两组总生存获益相似,老年组HR 0.45(95%CI 0.25-0.80),年轻组HR 0.71(95%CI 0.53-0.95);完成6周期化疗比例及3-5级不良事件率无显著差异。

要点

  • ≥70岁mHSPC患者从多西他赛+ADT中获总生存获益,HR 0.45。
  • 老年与年轻患者完成6周期多西他赛比例及3-5级不良事件率无显著差异。
  • 体能适合化疗的老年mHSPC患者可考虑多西他赛治疗。

核心结论

  • 老年mHSPC患者接受多西他赛+ADT的总生存获益与年轻患者相似。

研究设计与样本

  • CHAARTED随机试验的事后分析,比较≥70岁与<70岁mHSPC患者,采用Cox比例风险模型评估OS。

主要发现

  • 多西他赛+ADT改善OS:老年组HR 0.45(95%CI 0.25-0.80),年轻组HR 0.71(95%CI 0.53-0.95)。
  • 老年高瘤负荷亚组HR 0.43(95%CI 0.23-0.79),新发转移亚组HR 0.36(95%CI 0.19-0.69)。
  • 完成6周期多西他赛比例老年组82.6% vs 年轻组87.1%(p=0.28)。
  • 3-5级不良事件率老年组36.8% vs 年轻组26.8%(p=0.069),4-5级不良事件率14.9% vs 11.9%(p=0.46)。
  • 对照组中老年患者接受后续治疗比例34.4% vs 51.5%(p=0.017),后续多西他赛比例25.6% vs 37.6%(p=0.035)。

临床怎么用

  • 对体能适合化疗的老年mHSPC患者,多西他赛+ADT应作为 favorable 治疗选择。

局限性

  • 为事后分析,样本中≥70岁患者177例(22.4%),结论需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Most men who die of prostate cancer are older than 70 years. The ChemoHormonal Therapy Versus Androgen Ablation Randomized Trial for Extensive Disease in Prostate Cancer (CHAARTED) randomized men of all ages with metastatic hormone-sensitive prostate cancer (mHSPC) to receive androgen deprivation therapy (ADT) with or without docetaxel demonstrating an overall survival (OS) benefit for docetaxel. METHODS: In a post-hoc analysis of this trial, we assessed patient characteristics and OS in patients ≥70 years ("older men") versus <70 years ("younger men") with Cox proportional hazards models. In addition, we compared adverse events, therapy completion rate, and subsequent treatment patterns between these two groups using Chi-squared tests. RESULTS: 177 (22.4%) patients were ≥70 years. Docetaxel + ADT resulted in improved OS in both older and younger men (Hazard Ratio [HR] 0.45, 95%CI: 0.25-0.80 for older men; HR 0.71, 95%CI: 0.53-0.95 for younger men). This treatment benefit was seen for subgroups of older men with high volume disease (HR 0.43, 95%CI 0.23-0.79) and de novo metastatic disease (HR 0.36, 95%CI 0.19-0.69). A similar proportion of older and younger men completed six cycles of docetaxel (82.6% vs. 87.1%, p = 0.28). Rates of grade 3-5 adverse events were similar between older and younger men (36.8% vs. 26.8%, respectively, p = 0.069). The rate of any Grades 4-5 adverse events did not differ significantly between older and younger men (14.9% vs. 11.9%, respectively, p = 0.46). In the control arm, a smaller proportion of older men received subsequent cancer treatments (34.4% vs. 51.5%, p = 0.017) or subsequent docetaxel (25.6% vs. 37.6%, p = 0.035) compared to younger men. CONCLUSIONS: Older men with mHSPC had similar OS benefit and clinical outcomes compared to younger men when receiving docetaxel + ADT. Oncologists should consider docetaxel chemotherapy as a favorable treatment option for older men with mHSPC who are fit for chemotherapy.

来源:Prostate Cancer Prostatic Dis,查看原文。版权归原作者所有。

引用

  1. Lage DE, Michaelson MD, Lee RJ, et al. Outcomes of older men receiving docetaxel for metastatic hormone-sensitive prostate cancer. Prostate Cancer Prostatic Dis. 2021. PMID: 34007017. doi:10.1038/s41391-021-00389-2

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。